[go: up one dir, main page]

PL3179986T3 - Suche formulacje w proszku do inhalacji - Google Patents

Suche formulacje w proszku do inhalacji

Info

Publication number
PL3179986T3
PL3179986T3 PL15827152.8T PL15827152T PL3179986T3 PL 3179986 T3 PL3179986 T3 PL 3179986T3 PL 15827152 T PL15827152 T PL 15827152T PL 3179986 T3 PL3179986 T3 PL 3179986T3
Authority
PL
Poland
Prior art keywords
inhalation
dry powder
powder formulations
formulations
dry
Prior art date
Application number
PL15827152.8T
Other languages
English (en)
Inventor
Kambiz Yadidi
Original Assignee
Vectura Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55218356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3179986(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Inc. filed Critical Vectura Inc.
Publication of PL3179986T3 publication Critical patent/PL3179986T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15827152.8T 2014-07-31 2015-07-31 Suche formulacje w proszku do inhalacji PL3179986T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031811P 2014-07-31 2014-07-31
PCT/US2015/043128 WO2016019253A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation

Publications (1)

Publication Number Publication Date
PL3179986T3 true PL3179986T3 (pl) 2023-06-26

Family

ID=55218356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15827152.8T PL3179986T3 (pl) 2014-07-31 2015-07-31 Suche formulacje w proszku do inhalacji

Country Status (10)

Country Link
EP (2) EP4218734A1 (pl)
JP (1) JP6850524B2 (pl)
KR (2) KR102666667B1 (pl)
CN (2) CN107072947A (pl)
AU (2) AU2015296142A1 (pl)
CA (1) CA2991760C (pl)
DK (1) DK3179986T3 (pl)
ES (1) ES2942297T3 (pl)
PL (1) PL3179986T3 (pl)
WO (1) WO2016019253A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
EP3463378A4 (en) * 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
CN115919780A (zh) * 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP4311566A1 (en) 2022-07-28 2024-01-31 Vectura Inc. An inhaler comprising a retention element

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
WO1996032151A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US20010055610A1 (en) * 1997-06-06 2001-12-27 Shunji Nagata Medicament administration system
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DE69814428T2 (de) 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
EP1750674A4 (en) * 2004-05-27 2012-05-23 Advanced Bionutrition Corp MICROPARTICLES FOR THE ORAL LEVY
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
MX2007012045A (es) * 2005-03-28 2008-01-16 Pericor Therapeutics Inc Composiciones y formulaciones para evitar o reducir efectos adversos a un paciente.
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
DK2252275T3 (en) 2008-02-13 2018-03-05 Univ Texas CREATED NON-OPEN FLOCKS OF ANISOTROPIC PARTICLES FOR IMPROVED TRANSPORT INTO THE Lungs
US20120160944A1 (en) * 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
AU2013227351B2 (en) * 2012-02-28 2016-06-16 Iceutica Holdings Inc. Inhalable pharmaceutical compositions
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
DK3107548T3 (da) * 2014-02-20 2022-07-18 Otitopic Inc Tørpulverformuleringer til inhalation

Also Published As

Publication number Publication date
EP4218734A1 (en) 2023-08-02
CN107072947A (zh) 2017-08-18
AU2020203437A1 (en) 2020-06-11
KR20170039255A (ko) 2017-04-10
CA2991760C (en) 2025-05-06
DK3179986T3 (da) 2023-05-01
JP6850524B2 (ja) 2021-03-31
EP3179986A1 (en) 2017-06-21
WO2016019253A9 (en) 2016-05-12
KR102603897B1 (ko) 2023-11-20
WO2016019253A1 (en) 2016-02-04
EP3179986B1 (en) 2023-03-15
JP2017523189A (ja) 2017-08-17
EP3179986A4 (en) 2018-02-07
CN116687887A (zh) 2023-09-05
AU2020203437B2 (en) 2020-09-17
AU2015296142A1 (en) 2017-02-23
ES2942297T3 (es) 2023-05-31
KR102666667B1 (ko) 2024-05-17
KR20230119032A (ko) 2023-08-14
CA2991760A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
PL3107548T3 (pl) Suche formulacje w proszku do inhalacji
ZA201606073B (en) Nicotine powder inhaler
IL257004B (en) Dry powder inhaler
ZA201703077B (en) Dry powder inhaler
GB2522492B (en) Dry powder processing
SMT202000683T1 (it) Inalatore di polvere
PL3138601T3 (pl) Inhalator suchego proszku
GB201419091D0 (en) Formulations
GB201419261D0 (en) Formulations
IL263365A (en) Dry powder inhaler
IL251665A0 (en) Dry powder formulation
PL3179986T3 (pl) Suche formulacje w proszku do inhalacji
EP3463378A4 (en) DRY POWDER FORMULAS FOR INHALATION
IL249773A0 (en) Breaks up lumps of dry powder medicine
IL249774A0 (en) Dry powder nebulizer
IL249398A0 (en) A dry powder inhaler that is activated by breathing
GB2542283B (en) Dry powder fire-fighting composition
ZA201702717B (en) Powder formulation
GB201511942D0 (en) Dry powder inhaler apparatus
HK1240151A1 (en) Dry powder inhaler
GB201511950D0 (en) Dry powder inhaler apparatus
IL247557A0 (en) Nicotine powder inhaler
HK1230118A1 (en) Dry powder inhaler
HK1243010A1 (en) Dry powder medicament de-agglomerator
HK1238585A1 (en) Dry powder nebulizer